SAN DIEGO, CA, January 4, 2018 – Recros Medica, Inc., a development stage medical aesthetic device company focused on reducing skin laxity and focal contouring, announced today that it has closed a $9M financing. Additionally, the company is strengthening its Board of Directors with the additions of Christoph Westphal, MD, PhD and Mark Kerslake.
“We are grateful for the additional financial resources to expand our company and accelerate our product and clinical development programs. This financing, which includes an investment from the prestigious Longwood Fund, underscores the potential of our technology platforms in the rapidly growing aesthetics market,” stated Tom Albright, President and CEO of Recros Medica.
Dr. Westphal is a co-founder and Partner of the Longwood Fund. Dr. Westphal was co-founder, CEO, and lead investor of six biotech companies that have completed IPOs: Momenta, Alnylam, Acceleron Pharmaceuticals, Sirtris (acquired by GSK), Verastem, and Flex. He co-founded two additional companies that completed IPOs: Concert Pharmaceuticals, and OvaScience. He also co-founded Alnara (acquired by Lilly), and Axial. Dr. Westphal’s companies have created substantial shareholder value, with aggregate market capitalizations of over $15 billion, and have contributed to the creation of over 1,000 jobs. Dr. Westphal earned his M.D. from Harvard Medical School and Ph.D. in genetics from Harvard University.
Mr. Kerslake is Principal of the Province Group, a Newport Beach, CA real estate development and investment company active in the acquisition, entitlement, management, and disposition of residential and mixed-use real estate projects in multiple states. Mr. Kerslake has considerable experience in transactional structuring, financial engineering and high-level negotiations with buyers, sellers, lenders and institutional financial partners. Mr. Kerslake holds a MBA from UCLA.
“Adding Christoph and Mark to our Board, with their significant business expertise and financial acumen, will enhance our ability to properly execute the strategic vision of this innovative company,” said David F. Hale, Chairman of the Board of Recros Medica.